News Archive

The Patient-Centered Outcomes Research Institute has funded up to $50 million to evaluate hydroxychloroquine as a preventive drug for the novel coronavirus.

When compared to patients with non-advanced heart failure, patients with advanced heart failure had a more than three-fold higher risk of dying within a year after receiving a defibrillator.

The award honors Douglas’ work in diversity and inclusion in the field of cardiology.

A novel composite risk model showed that 11 percent of sites had worse-than-expected performance, with patients experiencing higher rates of stroke, major bleeding, kidney injury, and paravalvular leak in the 30 days after undergoing a transcatheter aortic valve replacement.

The DCRI’s Manesh Patel, MD, who was a member of the steering committee for this late-breaking clinical trial, has been working for years to determine the best treatment strategies for patients with peripheral artery disease.

DCRI faculty contributed to a recently published an updated meta-analysis that analyzed data from five clinical trials to compare four treatment options for patients with atrial fibrillation undergoing percutaneous coronary intervention.

Representatives of the DCRI and Duke Forge contributed to a paper that recommended the NIH strengthen its data sharing requirements, beginning by requiring sharing of clinical trial data.

The coronavirus outbreak has limited in-person research, highlighting the need for more flexible, participant-friendly research models that can be conducted virtually.

Former FDA Commissioners Mark McClellan, MD, PhD, director of the Duke-Margolis Center for Health Policy, and Scott Gottlieb, MD, made recommendations for how the FDA should respond to the novel co

Elements from ADAPTABLE could be implemented in future trials to make them more efficient, the paper’s authors write.